Information Provided By:
Fly News Breaks for May 9, 2019
IONS
May 9, 2019 | 20:46 EDT
Piper Jaffray analyst Tyler Van Buren kept his Neutral rating and $75 price target on Ionis Pharmaceuticals after its Q1 results with Spinraza royalties and Tegsedi sales seen "in line with expectations". The analyst believes that the company's pipeline is maturing as it gets ready to launch Waylivra in Europe next quarter and also sees its Huntington's OLE continuing to progress. Van Buren contends that Ionis Pharmaceuticals stock is "becoming more interesting" from a long term investment perspective given the recent pullback in price.
News For IONS From the Last 2 Days
IONS
Mar 28, 2024 | 10:40 EDT
Meetings to be held in Los Angeles on April 2 and in San Francisco on April 3 hosted by Piper Sandler.